JPRN-jRCT2080224633已完成3 期
A multi-center, open-label study to investigate the safety/tolerability and efficacy
未提供0 个研究点目标入组 66 人开始时间: 2019年4月11日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 66
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •*Diagnosis of chronic spontaneous urticaria for at least 6 months
- •*Diagnosis of chronic spontaneous urticaria refractory to standard of care at time of randomization
排除标准
- •*History of hypersensitivity to any of the study drugs or their excipients or to drugs of similar chemical classes
- •*Clearly defined, predominant trigger of their chronic inducible urticaria
- •*Evidence of parasitic infection
- •*Any other skin disease associated with chronic itching that might influence in the investigators opinion the study evaluations and results
- •*Prior exposure to ligelizumab
- •*Any H2 antihistamine, LTRA (montelukast or zafirlukast) or H1 antihistamines use at greater than approved doses after Visit 1.
- •Other protocol defined inclusion/exclusion may apply
研究者
相似试验
进行中（未招募）
不适用
Maintenance Study Including Re-induction Therapy for Patients Who Did Not Show a Clinical Effect in Study C87037 (2014-004399-42)EUCTR2014-004400-30-Outside-EU/EEACB Japan Co., Ltd.46
招募中
4 期
A Multi-Centre, Open label Study to Investigate the Recovery of Interferon-b Efficacy in Relapsing-Remitting Multiple Sclerosis Patients with Neutralising IFN-b Antibodies and Reduced Bioavailability.Relapsing-remitting Multiple SclerosisNeurological - Multiple sclerosisACTRN12605000657628Biogen Idec Australia Pty Ltd20
进行中（未招募）
不适用
A study to investigate the pharmacokinetics in children (aged 1 month to 17 years) with epilepsy, prescribed lacosamide.EpilepsyEUCTR2014-002629-36-Outside-EU/EEACB Biosciences, Inc32
进行中（未招募）
1 期
Study to investigate the effectiveness and safety of AOP Landiolol in controlling supraventricular tachycardia in children.Supraventricular tachycardia in pediatric patients.MedDRA version: 20.0Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: PTClassification code 10074640Term: Junctional ectopic tachycardiaSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: PTClassification code 10042604Term: Supraventricular tachycardiaSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: PTClassification code 10003662Term: Atrial flutterSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: PTClassification code 10040752Term: Sinus tachycardiaSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: PTClassification code 10003668Term: Atrial tachycardiaSystem Organ Class: 10007541 - Cardiac disordersEUCTR2015-001129-17-DEAOP Orphan Pharmaceuticals GmbH60
进行中（未招募）
1 期
Study to investigate the effectiveness and safety of AOP Landiolol in controlling supraventricular tachycardia in children.Supraventricular tachycardia in pediatric patients.MedDRA version: 20.0Level: LLTClassification code 10003859Term: AV reentrant tachycardiaSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: PTClassification code 10074640Term: Junctional ectopic tachycardiaSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: PTClassification code 10042604Term: Supraventricular tachycardiaSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: LLTClassification code 10052350Term: Multifocal atrial tachycardiaSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: PTClassification code 10003662Term: Atrial flutterSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: PTClassification code 10040752Term: Sinus tachycardiaSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: LLTClassification code 10003857Term: AV nodal reentrant tachycardiaSystem Organ Class: 10007541 - Cardiac disordersEUCTR2015-001129-17-LTAOP Orphan Pharmaceuticals AG60